203 related articles for article (PubMed ID: 15274324)
1. The breakdown of apoptotic mechanism in the development and progression of colorectal carcinoma.
Ogawa S; Nagao M; Kanehiro H; Hisanaga M; Ko S; Ikeda N; Nakajima Y
Anticancer Res; 2004; 24(3a):1569-79. PubMed ID: 15274324
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
Gratas C; Tohma Y; Barnas C; Taniere P; Hainaut P; Ohgaki H
Cancer Res; 1998 May; 58(10):2057-62. PubMed ID: 9605741
[TBL] [Abstract][Full Text] [Related]
3. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence.
Belluco C; Esposito G; Bertorelle R; Alaggio R; Giacomelli L; Bianchi LC; Nitti D; Lise M
Eur J Surg Oncol; 2002 Mar; 28(2):120-5. PubMed ID: 11884046
[TBL] [Abstract][Full Text] [Related]
4. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
[TBL] [Abstract][Full Text] [Related]
5. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
7. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.
Okada K; Komuta K; Hashimoto S; Matsuzaki S; Kanematsu T; Koji T
Clin Cancer Res; 2000 Sep; 6(9):3560-4. PubMed ID: 10999744
[TBL] [Abstract][Full Text] [Related]
8. p53 promotes selection for Fas-mediated apoptotic resistance.
Maecker HL; Koumenis C; Giaccia AJ
Cancer Res; 2000 Aug; 60(16):4638-44. PubMed ID: 10969818
[TBL] [Abstract][Full Text] [Related]
9. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
10. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
Nagao M; Nakajima Y; Hisanaga M; Kayagaki N; Kanehiro H; Aomatsu Y; Ko S; Yagita H; Yamada T; Okumura K; Nakano H
Hepatology; 1999 Aug; 30(2):413-21. PubMed ID: 10421649
[TBL] [Abstract][Full Text] [Related]
11. Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression.
Prado-Garcia H; Aguilar-Cazares D; Meneses-Flores M; Morales-Fuentes J; Lopez-Gonzalez JS
Cancer Immunol Immunother; 2008 Mar; 57(3):325-36. PubMed ID: 17668204
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.
Das H; Koizumi T; Sugimoto T; Chakraborty S; Ichimura T; Hasegawa K; Nishimura R
Br J Cancer; 2000 May; 82(10):1682-8. PubMed ID: 10817504
[TBL] [Abstract][Full Text] [Related]
13. Fas ligand expression in esophageal carcinomas and their lymph node metastases.
Younes M; Schwartz MR; Ertan A; Finnie D; Younes A
Cancer; 2000 Feb; 88(3):524-8. PubMed ID: 10649242
[TBL] [Abstract][Full Text] [Related]
14. Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma.
Li SY; Yu B; An P; Wei JC; Zuo FY; Cai HY
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):226-9. PubMed ID: 15138115
[TBL] [Abstract][Full Text] [Related]
15. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
[TBL] [Abstract][Full Text] [Related]
16. Fas labeling status does not correlate with apoptosis of renal cell carcinoma in vivo.
Koga F; Arai K; Kamai T; Abe H; Yoshida K
Anticancer Res; 2001; 21(5):3193-7. PubMed ID: 11848472
[TBL] [Abstract][Full Text] [Related]
17. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
18. Close localization of DAP-kinase positive tumour-associated macrophages and apoptotic colorectal cancer cells.
Schneider-Stock R; Kuester D; Ullrich O; Mittag F; Habold C; Boltze C; Peters B; Krueger S; Hintze C; Meyer F; Hartig R; Roessner A
J Pathol; 2006 May; 209(1):95-105. PubMed ID: 16575786
[TBL] [Abstract][Full Text] [Related]
19. FasL:Fas ratio--a prognostic factor in breast carcinomas.
Reimer T; Herrnring C; Koczan D; Richter D; Gerber B; Kabelitz D; Friese K; Thiesen HJ
Cancer Res; 2000 Feb; 60(4):822-8. PubMed ID: 10706087
[TBL] [Abstract][Full Text] [Related]
20. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications.
Korkolopoulou P; Saetta AA; Levidou G; Gigelou F; Lazaris A; Thymara I; Scliri M; Bousboukea K; Michalopoulos NV; Apostolikas N; Konstantinidou A; Tzivras M; Patsouris E
Histopathology; 2007 Aug; 51(2):150-6. PubMed ID: 17559541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
